Kelechi Azuogu, MD
General Practice · Houston, TXNPI 1003220625
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Galderma Laboratories, L.p. at 43.9% of the total. 2023 is the largest year on record at $163, 2.2 times the $73 reported in 2019.
Across 19 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$181
- AbbVie$61
- Lilly USA, LLC$58
- Pacira Therapeutics, Inc.$53
- GSK$32
- Johnson & Johnson$14
- plus $14 from 1 others
Across 145 payments — averaging $17,573 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Partner Therapeutics, Inc.$1.5M
- Merck$466K
- Modernatx, Inc.$195K
- Teva Pharmaceuticals USA, Inc.$151K
- Vanda Pharmaceuticals Inc.$84K
- GSK$48K
- plus $113K from 6 others
What the payments were for
- Food & beverage$411100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 6 | $181 |
| AbbVie | 3 | $61 |
| Lilly USA, LLC | 3 | $58 |
| Pacira Therapeutics, Inc. | 3 | $53 |
| GSK | 2 | $32 |
| Johnson & Johnson | 1 | $14 |
| Pfizer | 1 | $14 |
How this compares
$411 in reported general payments places this provider in the 65th percentile of 8,074 general practice providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 12 | $11,103 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $772 |
| Fluticasone Propionate | 11 | $431 |
| Pantoprazole Sodium | 17 | $429 |
| Atorvastatin Calcium | 59 | $251 |
| Duloxetine Hcl | 13 | $221 |
| Omeprazole | 12 | $184 |
| Allopurinol | 20 | $151 |
| Amlodipine Besylate | 32 | $146 |
| Rosuvastatin Calcium | 14 | $133 |
| Lisinopril | 16 | $96 |
| Metformin Hcl | 26 | $92 |
| Alendronate Sodium | 11 | $90 |
| Carvedilol | 17 | $73 |
| Trazodone Hcl | 16 | $56 |
Paid to pharmacies, not to this prescriber.
Other general practice in Houston
- Kathleen Szelei-StevensHouston$253K
- Zsolt GaramiHouston$111K
- Scott ColemanHouston$87K
- Rispba McCray-GarrisonHouston$70K
- Piya GandhiHouston$36K
- Terri AlaniHouston$30K
- Demetris GreenHouston$26K
- Steven XueHouston$19K
- Carol DupuisHouston$16K
- Rosita HamidiHouston$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.